Hello everybody. Thank you for tuning into psychedelics. Today's podcast with myself, David Drapkin, in conversation with Hans Erickson. He is at HMNC Brain Health as a chief clinical development officer.

We had a really cool chat back in the summer.

So it's a while ago, but I remember ending the conversation feeling like, wow, I didn't know that stuff was happening.

I didn't realize that, yeah, psychedelic molecules are being used

just so kind of precision. And that's what he actually goes into talking about, precision psychiatry.

And having worked in psychiatry for quite a long time, particularly inpatient psychiatry,

I remember so many of the doctors I work with and even like the attendings and

the chiefs of the unit saying, David, we don't know how or why SSRIs work. We don't know

what they do on the brain, but we just know for some people they do work. But at the same time,

there's so many side effects that come from them and they don't

help, you know, so many people, about 30 to 40% of folks with depression, they just, you know,

treatment resistance is the term we use, they just don't work. So that's why we've got,

you know, these pharma companies trying to figure out how can we target different molecules for

treating those parts of the brain where depression kind of lives. And yet it's not just a

farmer play. There has to be, you know, more social, cultural, relational, epistemological components

built on top of what the molecule can do.

But I really loved hearing how they're using, for example, artificial intelligence to really

target the molecules into certain parts of the brain.

And for me, this is kind of deep science.

So I hope you enjoy it. For me, again, it's exploring the mind and the brain

and molecules. It's kind of like Star Trek and literally trying to find out new information and new

places, new relationships within the brain and consciousness itself. So I'll read out Hans's bio. Dr. Hans Erickson is a highly

...